ExeVir doses first patients with llama-derived anti-Covid antibody
A little over five months after pulling in a $50 million Series A, ExeVir is ready to take the next step with its llama-derived Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
